Adherium wins “Most Innovative Hi-Tech Hardware Product Award’ at the 2017 NZ High Tech Awards

15/05/2017 – link here Adherium have come out on top at this year’s Hi-Tech Awards, claiming the coveted Hi-Tech Hardware Product award. Over 900 people attended the awards ceremony, which celebrates the successes of New Zealand hi-tech companies across 13 categories. In selecting Adherium as Most Innovative Hi-Tech Hardware Product, the international judges said, “Adherium has […]

Avita Medical initiates legal proceedings to cancel Renovacare patent

Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, 11 May 2017 — link here Avita Medical Limited (ASX:AVH; OTCQX:AVMXY), a regenerative medicine company focused on the treatment of wounds and skin defects, has filed an Inter Partes Review (IPR) petition against US Patent No. 9,610,430 (the ‘430 patent) owned by Renovacare Sciences Corp., as […]

AmpliPhi Biosciences Announces Closing of Public Offering

Wednesday, May 10, 2017 5:29 pm EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a biotechnology company focused on the development of therapies for drug-resistant bacterial infections using bacteriophage technology, today announced the closing of its previously announced underwritten public offering. Total proceeds […]

Initial Pre-Emergency Use Authorization submission made to U.S. FDA for use of ReCell® in a Mass Casualty Scenario

Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, 10 May 2017 — link here Avita Medical Limited (ASX:AVH; OTCQX:AVMXY), a regenerative medicine company focused on the treatment of wounds and skin defects, has received notification of the initial FDA review of the Pre-EUA (Emergency Use Authorization) submission to allow the emergency deployment of its […]

AmpliPhi Biosciences Announces Pricing of $10.4 Million Underwritten Public Offering of Common Stock and Common Warrants

Thursday, May 4, 2017 10:02 pm EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a biotechnology company focused on the development of therapies for drug-resistant bacterial infections using bacteriophage technology, today announced the pricing of an underwritten public offering of 6,956,522 shares of […]

AmpliPhi Biosciences Announces a New Strategic Emphasis on Personalized Therapies for Serious or Life-Threatening Antibiotic-Resistant Infections

Monday, May 1, 2017 6:50 am EDT – Link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “stated that the clinical safety and effectiveness data collected during development, including from emergency case studies, could inform future discussions for clinical development and, ultimately, the regulatory pathway to approval.” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: […]

‘The enemy of my enemy is my friend:’ Couple turns to viruses to beat back superbug

Man with desperate infection rescued 100 years after Canadian co-discovery of phages By Amina Zafar, CBC News Posted: Apr 28, 2017 8:14 PM ET Last Updated: Apr 29, 2017 7:32 AM ET – Link here It may seem like an unlikely option, but it was viruses that helped to save Tom Patterson when a superbug threatened his life. Patterson fell […]

AmpliPhi Biosciences Announces Presentation of Personalized Bacteriophage Therapy Case Study for Life-Threatening Antibiotic-Resistant Infection at Scientific Conference

Tuesday, April 25, 2017 6:50 am EDT – Link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “Intravenous applications of phage therapy to treat a terminally ill patient who was infected with a multidrug-resistant A. baumannii” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for drug-resistant […]

AmpliPhi Biosciences Announces Positive Feedback from FDA on Phase 2 Development Proposal

Monday, April 17, 2017 9:00 am EDT – Link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “I’m extremely proud of the entire AmpliPhi team, including academic collaborators, clinical investigators and consultants, for their efforts in successfully positioning our phage technology to enter the Phase 2 development stage, which we expect will open additional […]

AmpliPhi Biosciences Announces Planned One-for-Ten Reverse Stock Split

Friday, April 14, 2017 5:00 pm EDT – Link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “We believe the increased market price of our common stock expected to result following the implementation of the reverse stock split may improve the marketability and liquidity of our common stock and encourage interest and trading in […]